160d OCT 0 1 2002

Attorney Docket No.: CIR 2-001-3

### PATENT AND TRADEMARK OFFICE

re Application of

Richard G. Olsen, et al.

Serial No. 09/125,841 Examiner Ronald B. Schwadron, Ph.D.

Filed: January 19, 1999 Group Art Unit 1644

RECEIVED For: Cellular Immunotherapy OCT 1 5 2002

COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

**TECH CENTER 1600/2900** 

### TRANSMITTAL LETTER

Sir:

Responsive to the outstanding Office action mailed on September 3, 2002 (paper no. 22), we are transmitting herewith:

- 1. Response to Notice of Sequence Listing Requirements and Amendment
- 2. Paper copy of Sequence Report
- 3. Computer diskette labeled US09125841.
- 4. Copy of CRF Disk Problem Report dated 6/21/02.

Respectfully submitted,

K. Mueller, Reg. No. 27,576

MUELLER AND SMITM, L MUELLER-SMITH BUILDING 7700 Rivers Edge Drive Columbus, Ohio 43235-1335

Tel.: 614-436-0600 Fax: 614-436-0057

email: smueller@muellersmith.com

#### **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited on September 23, 2002, with the United States Postal Service as first class mail in an envelope addressed to:

> Box RESPONSES NO FEE **Assistant Commissioner for Patents** Washington, D.C. 20231

Application No.: 09/125841


## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.	
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).	
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).	
A	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."	
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).	
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
	7. Other:	
Applicant Must Provide:		
囚	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	
A	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.	
Q	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).	
For	questions regarding compliance to these requirements, please contact:	
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 Patently software help, call (703) 308-6856	

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

## RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	09/125,841
Source:	1600
Date Processed by STIC:	6-21-0-

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4232

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)
PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 3.1 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK-OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">http://www.uspto.gov/ebc/efs/downloads/documents.htm</a>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
- 3. Hand Carry directly to:
  U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
  - U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
- 4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

### Raw Sequence Listing Error Summary .

•	,			
ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: <u>U9/12</u> 5, 84 / C			
attn: New Rules Cases: Please disregard english "Alpha" Headers, which were inserted by Pto Software				
lWrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."			
2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.			
3Misaligned Amino Numbering	The numbering under each 5 <sup>th</sup> amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.			
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.			
5Variable Length	Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.			
6PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.			
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:  (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)  (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  This sequence is intentionally skipped			
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.			
8Skipped Sequences (NEW RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence. <10> sequence id number <400> sequence id number 000			
(NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing.  Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.  In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.			
Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence			
	Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.  (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)			
"bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.			

AMC - Biotechnology Systems Branch - 06/04/2001

# Does Not Comply Corrected Diskette Needed



1600

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/125,841C

DATE: 06/21/2002 TIME: 14:03:33

Input Set : A:\Cellular immonotherapy.txt
Output Set: N:\CRF3\06212002\I125841C.raw

```
3 <110> APPLICANT: Olsen, Richard G
         Ridihalgh, John L
 6 <120> TITLE OF INVENTION: Cellular Immunotherapy
 8 <130> FILE REFERENCE: CIR-2-001-3
10 <140> CURRENT APPLICATION NUMBER: US 09/125841C
11 <141> CURRENT FILING DATE: 1999-01-19
13 <150> PRIOR APPLICATION NUMBER: PCT/US97/02309
14 <151> PRIOR FILING DATE: 1997-02-20
16 <150> PRIOR APPLICATION NUMBER: US 08/604728
17 <151> PRIOR FILING DATE: 1996-02-21
19 <160> NUMBER OF SEQ ID NOS: 4
21 <170> SOFTWARE: PatentIn version 3.1
23 <210> SEQ ID NO: 1
24 <211> LENGTH: 28
25 <212> TYPE: DNA
                                          numeric identifier 12137 Can
26 <213> ORGANISM: HIV-1 primer
                                         only be Artificial Sequences Unknown, or genus/species. See Hem #10
28 <400> SEQUENCE: 1
29 ataatccacc tatcccagta ggagaaat
32 <210> SEQ ID NO: 2
33 <211> LENGTH: 28
34 <212> TYPE: DNA
35 <213> ORGANISM: HIV-1/primer
37 <400> SEQUENCE: 2
38 tttggtcctt gtcttatgtc cagaatgc
41 <210> SEQ ID NO: 3
42 <211> LENGTH: 22
43 <212> TYPE: DNA
44 <213> ORGANISM: ØADPH cDNA
46 <400> SEQUENCE: 3
47 ctactggcgc tgccaaggct gt
                                                                           22
50 <210> SEQ ID NO: 4
51 <211> LENGTH: 22
52 <212> TYPE: DNA
53 <213> ORGANISM: GADPH cDNA
55 <400> SEQUENCE: 4\
56 gccatgaggt ccaccaccct gt
                                                                           22
```

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/125,841C

DATE: 06/21/2002

TIME: 14:03:34

Input Set: A:\Cellular immonotherapy.txt
Output Set: N:\CRF3\06212002\I125841C.raw